Aster Capital Management’s TG Therapeutics TGTX Stock Holding History

Aster Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-62	Closed	-$1.85K	–	1313
2025 Q4	$1.85K	Buy	+62	New	+$2.02K	﹤0.01%	961
2025 Q2	–	Sell	-3,243	Closed	-$97.6K	–	1566
2025 Q1	$97.6K	Buy	+3,243	New	+$109K	0.02%	666

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Aster Capital Management's TGTX Position: Q1 2026 in Review

Aster Capital Management sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 62 shares — an estimated $1.85K sold.

Aster Capital Management first reported a position in TGTX in Q1 2025 and held it in 2 quarters. The position peaked at $97.6K in Q1 2025. 364 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Aster Capital Management reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
Aster Capital Management sold 62 TG Therapeutics shares in Q1 2026, an estimated $1.85K.
Aster Capital Management first reported a position in TG Therapeutics in Q1 2025 and held it in 2 quarters.
Aster Capital Management's TG Therapeutics position peaked at $97.6K in Q1 2025.
364 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.